Gastroesophageal Reflux Disease Market Size

Gastroesophageal Reflux Disease Market size was over USD 5.24 billion in 2024 and is expected to reach USD 7.13 billion by the end of 2037, witnessing around 2.4% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of gastroesophageal reflux disease (GERD) is estimated at USD 5.44 billion. 

The rising prevalence of functional gastrointestinal disorders (FGIDs) over the world is set to propel the growth of the market. A survey published by ScienceDirect in January 2021 revealed that over 40% of the world’s population suffered from this condition. Another report from Frontiers, released in September 2022, stated that GERD affected 33% of the total habitats around the globe. Further, risk factors such as older age, obesity, and sedentary lifestyle are proven to enlarge this patient pool. On this note, WHO predicted the number of people aged 60 and over to surpass 2.1 billion worldwide by 2050. Similarly, the World Heart Federation calculated the volume of obese residents to be 1.0 billion by 2030.

Furthermore, the increasing tendency to self-medicate is also positively impacting the growth of the market. Thus, the availability and accessibility of a strong and affordable medication pipeline is required to maintain the sector’s gain. To justify this need, Frontiers published a bibliometric and visualized study on the current scenario of associated R&D culture in September 2022. It highlighted the range of direct annual financial exhaustion to be USD 9.0-10.0 billion in the U.S., most of which was originated from the use of proton pump inhibitors (PPIs) as a first line therapy. This is bringing the focus of global leaders to develop more functionally and economically effective medicines to offer a liable payers’ pricing.